UR-5269

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameUR-5269
Drug Alias Namep38 Kinase inhibitor (UBE Industries/Summit Pharmaceuticals)rheumatoid arthritis therapy (UBE Industries)UR-5269
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionP38 α mitogen-activated protein kinase inhibitors
TargetsP38 α mitogen-activated protein kinase
Therapy Area/IndicationsArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesUbe Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUbe CorpSummit Pharmaceuticals International
Active IndicationsN/A
Inactive IndicationsArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksN/A